APA (7th ed.) Citation

A, S., KJ, S., D, T., EJ, W., E, W., GJ, N., . . . AA, M. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science translational medicine, 10(422), . https://doi.org/10.1126/scitranslmed.aam7577

Chicago Style (17th ed.) Citation

A, Samson, et al. "Intravenous Delivery of Oncolytic Reovirus to Brain Tumor Patients Immunologically Primes for Subsequent Checkpoint Blockade." Science Translational Medicine 10, no. 422 (2018). https://doi.org/10.1126/scitranslmed.aam7577.

MLA (9th ed.) Citation

A, Samson, et al. "Intravenous Delivery of Oncolytic Reovirus to Brain Tumor Patients Immunologically Primes for Subsequent Checkpoint Blockade." Science Translational Medicine, vol. 10, no. 422, 2018, https://doi.org/10.1126/scitranslmed.aam7577.